Turkey tail mushroom extracts have been studied for decades as add-ons to standard cancer treatment. The most consistent evidence links them to longer survival in stomach and colon cancer after surgery and chemotherapy, alongside better immune measures and quality of life. Generally well tolerated. How well the older findings hold up today remains genuinely uncertain. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Complete blood count with differential | Within healthy reference (lymphocytes ~1.5–3.5 ×10⁹/L) | Tracks immune cell recovery and bone-marrow effects of chemotherapy |
| Natural killer (NK) cell activity | Higher within normal range preferred | Directly reflects the proposed immune mechanism |
| Liver enzymes (ALT, AST) | ALT/AST in low-normal range (roughly <30 U/L) | Detects rare hepatic effects and contaminant-related harm |
| C-reactive protein (CRP) | <1.0 mg/L | Gauges systemic inflammation associated with disease and treatment |
| Tumor markers (e.g., CEA for colorectal, CA 19-9 for gastric) | Within assay reference range / declining trend | Tracks disease status during adjunct use |
| Vitamin D (25-hydroxyvitamin D) | 40–60 ng/mL | Supports immune function that underlies the intervention's rationale |
Cadence: Baseline, then aligned with the oncology schedule — every cycle or every 1–3 months during active treatment, and every 3–6 months thereafter